---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-129018"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:12:58.490254+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cyclacel raises $1.29M through registered direct and private placements of stock and warrants

## Summary
- Gross proceeds ~$1.29M from sale of 388,200 shares/pre-funded warrants at $3.315/share to institutional investors.
- Issues unregistered warrants to purchase 388,200 shares at $3.19 each, exercisable for 7 years.
- Insiders (CEO and CFO) purchase 7,956 shares and warrants on same terms in concurrent private placement.
- Ladenburg Thalmann acts as placement agent; fees 8% of gross proceeds plus warrants.
- Closing expected December 26, 2023; proceeds for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001104659-23-129018
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/tm2333683d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-129018
- JSON: https://secwatch.observer/filing/0001104659-23-129018.json
- Plain text: https://secwatch.observer/filing/0001104659-23-129018.txt

## Key facts
- Material Agreements
  Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain institutional investors ("Purchasers") valued at approximately $1.29 million (effective 2023-12-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors ("Purchasers")
  - Value: approximately $1.29 million
  - Effective: 2023-12-21
  source text: On December 21, 2023, Cyclacel Pharmaceuticals, Inc. (the "Company," "we" or "us") entered into a securities purchase agreement ("Securities Purchase Agreement") with certain institutional investors ("Purchasers").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm
- Material Agreements
  Bio Green Med Solution, Inc. entered into Securities Purchase Agreement with certain of our executive officers (effective 2023-12-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain of our executive officers
  - Effective: 2023-12-21
  source text: On December 21, 2023, in a separate concurrent insider private placement (the "Insider Private Placement"), we also entered into a Securities Purchase Agreement with certain of our executive officers (the "Insider Securities Purchase Agreement")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm
- Material Agreements
  Bio Green Med Solution, Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. (the "Placement Agent") (effective 2023-12-21).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Ladenburg Thalmann & Co. Inc. (the "Placement Agent")
  - Effective: 2023-12-21
  source text: Ladenburg Thalmann & Co. Inc. (the "Placement Agent") acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the "Placement Agency Agreement"), dated December 21, 2023, by and between the Company and the Placement Agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923129018/0001104659-23-129018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.